Hercules Capital, Inc. (NASDAQ:HTGC) reported an insider purchase by Director Robert P. Badavas, who bought 5,000 shares of the company's common stock on February 24, 2026. The shares were acquired at an average price of $15.01, with trade prices recorded between $15.01 and $15.02, for a total outlay of $75,050.
At the time of the transaction, HTGC was trading close to its 52-week low of $14.57 and was down 17% year-to-date. Following the purchase, Badavas's reported holdings include 1,412 shares held directly and 117,073 shares held indirectly through the Robert P. Badavas Trust of 2007.
The company is presented as a $2.75 billion market capitalization business that carries a dividend yield of 12.44% and a price-to-earnings ratio of 8.13. According to InvestingPro, HTGC has sustained dividend payments for 22 consecutive years.
Separately, Hercules Capital released preliminary estimates for fourth-quarter results. The firm's net asset value per share as of December 31, 2025 is projected to fall in a range between $12.10 and $12.16, which represents an increase of $0.05 to $0.11 per share from the prior quarter.
On the research front, Piper Sandler adjusted its coverage of Hercules Capital by moving the stock from Overweight to Neutral and lowering its price target from $20.50 to $17.50. The firm cited Hercules Capital's 35% exposure to the software sector and noted risk considerations related to potential disruptions from artificial intelligence as the basis for the change.
In another development included in the company's disclosures, Hercules Capital amended its loan agreement with Savara Inc. The amendment provides for up to an additional $75 million in funding that would become available upon FDA approval of Savara's investigational therapy, MOLBREEVI. The stated purpose of the potential funding is to support the launch activities for the drug.
Taken together, these items - an insider purchase, a small sequential NAV improvement, an analyst downgrade tied to sector concentration, and a contingent funding amendment tied to regulatory approval - outline recent activity shaping Hercules Capital's financial picture. The market context for the shares includes the stock's proximity to its 52-week low and its year-to-date decline.
Note on information: All transaction amounts, holdings, financial metrics, analyst actions, NAV ranges, and loan amendment details are reported as stated in company and research disclosures.